Form 4: Alphatec EVP Sponsel Awarded Over 400K RSUs

Alphatec Holdings, Inc. EVP of Sales, David Sponsel, was awarded 412,294 Restricted Stock Units (RSUs) on February 25, 2026, including performance-based awards and a portion in lieu of a cash bonus.

Summary

• David Sponsel, EVP of Sales at Alphatec Holdings, Inc. (ATEC), acquired a total of 412,294 Restricted Stock Units (RSUs) on February 25, 2026.
• This includes 205,094 performance-based RSUs for meeting FY2025 criteria, vesting in three equal installments on March 5, 2026, 2027, and 2028.
• An additional 93,410 RSUs were awarded, vesting in three equal installments on March 5, 2027, 2028, and 2029.
• 20,380 RSUs were granted in lieu of a portion of the 2025 cash bonus, vesting on December 4, 2026, based on the 30-day average trading price as of February 25, 2026.
• Two separate awards of up to 46,705 performance-based RSUs each (totaling 93,410 RSUs) were granted, contingent on achieving specific stock price targets ($25.00 by Dec 31, 2028, and $36.00 by Dec 31, 2030) or operational metrics by December 31, 2028, and December 31, 2030.
• Following these transactions, Sponsel beneficially owns 668,384 shares of common stock (non-derivative, which includes the 205,094, 93,410, and 20,380 RSU grants as per Table I reporting) and 93,410 derivative Restricted Stock Units (from the performance-based awards in Table II).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies strong alignment between executive incentives and long-term shareholder value through substantial equity awards, including challenging performance-based targets.

Positives

• Significant RSU awards to a key executive (EVP, Sales) align management incentives with shareholder value.
• A portion of the awards are performance-based, tied to achieving specific stock price targets ($25.00 and $36.00 per share) and operational metrics, indicating management confidence in future growth.
• The grant in lieu of a cash bonus suggests a preference for equity compensation, further aligning executive interests with long-term company performance.

Negatives

• No immediate cash inflow for the executive from these RSU grants, as they are unvested.
• The performance-based RSUs have challenging stock price targets ($25.00 by Dec 31, 2028, and $36.00 by Dec 31, 2030), which may not be met if market conditions or company performance falter.

Risks

• Failure to meet stock price targets or operational metrics could result in the forfeiture of performance-based RSUs.
• The value of the RSUs is subject to the future market price of Alphatec Holdings, Inc. common stock, which can fluctuate.
• Dilution risk for existing shareholders if a large number of RSUs vest and convert to common stock.

Future Outlook

The significant performance-based RSU awards indicate Alphatec's management is focused on achieving substantial stock price appreciation, targeting $25.00 by December 31, 2028, and $36.00 by December 31, 2030, alongside specific operational metrics. This suggests an optimistic long-term growth strategy.

Industry Context

StockSavvy.ai notes that equity-based compensation, particularly performance-based RSUs, is a common practice in the medical device and biotechnology sectors to incentivize executives and align their interests with long-term shareholder value. The specific stock price targets set for these awards suggest Alphatec aims for significant market capitalization growth, potentially outpacing some peers if these targets are met. This strategy is often employed by growth-oriented companies seeking to reward executives for achieving ambitious milestones.

Comparison to Industry Standards

• The use of performance-based RSUs with specific stock price and operational targets is consistent with best practices in executive compensation within the medical technology industry, similar to programs seen at companies like Stryker or Medtronic, which tie a portion of executive pay to long-term stock performance and strategic objectives.
• The vesting schedules, ranging from one to three years, are standard for RSU grants, providing a balance between retention and performance incentives.
• The targets of $25.00 and $36.00 per share represent substantial growth from current levels (assuming current price is below these targets, which is implied by them being future targets), indicating an aggressive growth outlook comparable to high-growth phases of successful medical device innovators.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased long-term value creation if performance targets are met, but also potential for dilution upon RSU vesting.
• Employees (Executive): Enhanced long-term compensation and incentive to drive company performance.

Next Steps

• Monitoring of Alphatec's common stock price performance against the $25.00 (by Dec 31, 2028) and $36.00 (by Dec 31, 2030) targets for performance-based RSU vesting.
• Tracking of operational metrics as determined by the compensation committee for additional performance-based RSU vesting conditions.
• Observation of RSU vesting dates on March 5, 2026, March 5, 2027, March 5, 2028, March 5, 2029, and December 4, 2026.

Key Dates

Recommendation

The significant RSU awards to a key executive, particularly the performance-based components tied to ambitious stock price targets, signal strong internal confidence in Alphatec's future growth trajectory. This aligns management's interests with long-term shareholder value. However, as a Form 4, it primarily reports compensation and does not provide new financial results or operational updates that would warrant an immediate 'buy' or 'sell' recommendation. The 'hold' recommendation reflects the positive signal from executive alignment while awaiting further operational and financial performance data to assess the likelihood of achieving these ambitious targets.

Keywords

Alphatec Holdings, ATEC, Restricted Stock Units, RSU, Insider Trading, Executive Compensation, Performance-Based Awards, Stock Awards, SEC Form 4